Contribute Try STAT+ Today

Good morning, everyone, and how are you today? We are just fine, thank you, although we will be somewhat distracted today by personal matters that will encroach on our usual routine of sending along interesting items. We apologize for any inconvenience, but a colleague or two will pick up the slack. Meanwhile, though, here are some tidbits to get you started. Hope you have a meaningful day and conquer the world …

Novartis was fined $49 million by South Korea, and insurance reimbursement was suspended for six months for two of its medicines as a result of bribing doctors from 2011 to 2016, Reuters reports. The lack of reimbursement means that patients must find alternative treatments. The move by the Ministry of Health and Welfare came after prosecutors indicted six Novartis executives on the charges last year. A trial is now underway.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.